April 4, 2017 / 6:37 PM / 8 months ago

BRIEF-Karyopharm reports interim Phase 2b SADAL data

April 4 (Reuters) - Karyopharm Therapeutics Inc :

* Karyopharm reports interim Phase 2b SADAL data at the 2017 American Association for Cancer Research annual meeting

* 28.6% overall response rate demonstrated with a median duration of greater than seven months

* Top-line data from SADAL study expected in mid-2018

* Should data confirm current results, plan to apply for accelerated approval for treatment of relapsed / refractory DLBCL

* Amending SADAL study protocol to become single-arm study focusing solely on single-agent selinexor dosed at 60mg twice weekly

* SADAL study being amended to reduce 14-week treatment-free period to 8 weeks in patients who achieved at least PR on most recent therapy

* Company plans to enroll up to an additional 90 patients to new 60mg single-arm cohort

* Patients who were refractory or did not achieve at least a PR on their prior therapy in SADAL study to continue 14-week treatment-free period Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below